Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: Results of a pilot study

Cancer Immunology, Immunotherapy

Volumn 60, Issue 8, 2011, Pages 1097-1107

  Bauer, Christian ^a   Dauer, Marc ^c   Saraj, Samira ^a   Schnurr, Maximilian ^a   Bauernfeind, Franz ^a   Sterzik, Alexander ^a   Junkmann, Jana ^a   Jakl, Veronika ^a   Kiefl, Rosemarie ^a   Oduncu, Fuat ^a   Emmerich, Bertold ^a   Mayr, Doris ^b   Mussack, Thomas ^b   Bruns, Christiane ^b   Rüttinger, Dominik ^b   Conrad, Claudius ^b,d   Jauch, Karl Walter ^b   Endres, Stefan ^a   Eigler, Andreas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dendritic cell; Immunotherapy; Pancreatic cancer; Vaccination

Indexed keywords

DENDRITIC CELL VACCINE; GEMCITABINE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER IMMUNIZATION; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL LYSATE; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEASIBILITY STUDY; FEMALE; FREEZE THAWING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; TISSUE SECTION; TREATMENT RESPONSE; VACCINE PRODUCTION;

ADULT; AGED; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA; DENDRITIC CELLS; DINOPROSTONE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PILOT PROJECTS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960900889     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1023-5     Document Type: Article

References (29)

1. RF Ozols RS Herbst YL Colson J Gralow J Bonner WJ Curran Jr BL Eisenberg PA Ganz BS Kramer MG Kris M Markman RJ Mayer D Raghavan GH Reaman R Sawaya RL Schilsky LM Schuchter JW Sweetenham LT Vahdat RJ Winn 2007 Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening-a report from the American society of clinical oncology J Clin Oncol 25 1 146 162 10.1200/JCO.2006.09.7030 17158528 10.1200/JCO.2006.09.7030 1:CAS:528:DC%2BD2sXht1ejs7c%3D (Pubitemid 350003060)
2. HA Burris 3rd MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
3. ML Rothenberg MJ Moore MC Cripps JS Andersen RK Portenoy HA Burris 3rd MR Green PG Tarassoff TD Brown ES Casper AM Storniolo DD Von Hoff 1996 A phase ii trial of gemcitabine in patients with 5-fu-refractory pancreas cancer Ann Oncol 7 4 347 353 8805925 1:STN:280:DyaK28zpvFCgsA%3D%3D (Pubitemid 26246785)
4. C Louvet R Labianca P Hammel G Lledo MG Zampino T Andre A Zaniboni M Ducreux E Aitini J Taieb R Faroux C Lepere A de Gramont 2005 Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a gercor and giscad phase iii trial J Clin Oncol 23 15 3509 10.1200/JCO.2005.06.023 15908661 10.1200/JCO.2005.06. 023 1:CAS:528:DC%2BD2MXlsVyhsrg%3D
5. M Dauer M Schnurr A Eigler 2008 Dendritic cell-based cancer vaccination: Quo vadis? Expert Rev Vaccines 7 7 1041 1053 10.1586/14760584.7.7.1041 18767953 10.1586/14760584.7.7.1041 1:CAS:528:DC%2BD1cXhtVOiur7K
6. PW Kantoff CS Higano NDE Shore R Berger EJ Small DF Penson CH Redfern AC Ferrari R Dreicer RB Sims Y Xu MW Frohlich PF Schellhammer 2010 Sipuleucel-t immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411 422 20818862 10.1056/NEJMoa1001294 1:CAS:528:DC%2BC3cXhtVGlurrN
7. RM Steinman J Banchereau 2007 Taking dendritic cells into medicine Nature 449 7161 419 426 10.1038/nature06175 17898760 10.1038/nature06175 1:CAS:528:DC%2BD2sXhtV2is7%2FI (Pubitemid 47509552)
8. P Chaux N Favre M Martin F Martin 1997 Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible b7 expression in rats Int J Cancer 72 4 619 624 10.1002/(SICI)1097-0215(19970807)72:4<619:: AID-IJC12>3.0.CO;2-6 9259401 10.1002/(SICI)1097-0215(19970807)72:4<619:: AID-IJC12>3.0.CO;2-6 1:CAS:528:DyaK2sXls1Wlsrs%3D (Pubitemid 27356163)
9. AJ Troy KL Summers PJ Davidson CH Atkinson DN Hart 1998 Minimal recruitment and activation of dendritic cells within renal cell carcinoma Clin Cancer Res 4 3 585 593 9533525 1:STN:280:DyaK1c7pt1WqtA%3D%3D (Pubitemid 28193556)
10. M Dauer V Lam H Arnold J Junkmann R Kiefl C Bauer M Schnurr S Endres A Eigler 2008 Combined use of toll-like receptor agonists and prostaglandin e(2) in the fastdc model: Rapid generation of human monocyte-derived dendritic cells capable of migration and il-12p70 production J Immunol Methods 337 2 97 105 10.1016/j.jim.2008.07.003 18657542 10.1016/j.jim.2008.07.003 1:CAS:528:DC%2BD1cXhtVagsL3N
11. M Dauer B Obermaier J Herten C Haerle K Pohl S Rothenfusser M Schnurr S Endres A Eigler 2003 Mature dendritic cells derived from human monocytes within 48 h: a novel strategy for dendritic cell differentiation from blood precursors J Immunol 170 8 4069 4076 12682236 1:CAS:528:DC%2BD3sXisleku70%3D (Pubitemid 36428169)
12. M Schnurr P Galambos C Scholz F Then M Dauer S Endres A Eigler 2001 Tumor cell lysate-pulsed human dendritic cells induce a t-cell response against pancreatic carcinoma cells: An in vitro model for the assessment of tumor vaccines Cancer Res 61 17 6445 6450 11522639 1:CAS:528:DC%2BD3MXmsF2jsb8%3D (Pubitemid 32783250)
13. L Zitvogel L Apetoh F Ghiringhelli G Kroemer 2008 Immunological aspects of cancer chemotherapy Nat Rev Immunol 8 1 59 73 10.1038/nri2216 18097448 10.1038/nri2216 1:CAS:528:DC%2BD2sXhsVKrsLnP
14. E Suzuki V Kapoor AS Jassar LR Kaiser SM Albelda 2005 Gemcitabine selectively eliminates splenic gr-1 +/cd11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin Cancer Res 11 18 6713 6721 10.1158/1078-0432.CCR-05-0883 16166452 10.1158/1078-0432.CCR-05- 0883 1:CAS:528:DC%2BD2MXhtVShsb3O (Pubitemid 41339014)
15. AK Nowak RA Lake AL Marzo B Scott WR Heath EJ Collins JA Frelinger BW Robinson 2003 Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific cd8 t cells J Immunol 170 10 4905 4913 12734333 1:CAS:528:DC%2BD3sXjsVGqsro%3D (Pubitemid 36554719)
16. M Dauer J Herten C Bauer F Renner K Schad M Schnurr S Endres A Eigler 2005 Chemosensitization of pancreatic carcinoma cells to enhance t cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells J Immunother 28 4 332 342 16000951 10.1097/01.cji.0000164038.41104.f5 (Pubitemid 40962326)
17. C Bauer F Bauernfeind A Sterzik M Orban M Schnurr HA Lehr S Endres A Eigler M Dauer 2007 Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut 56 9 1275 1282 10.1136/gut.2006.108621 17395611 10.1136/gut.2006.108621 1:CAS:528: DC%2BD2sXhtVKgsbbN (Pubitemid 47300430)
18. Y Hirooka A Itoh H Kawashima K Hara K Nonogaki T Kasugai E Ohno T Ishikawa H Matsubara M Ishigami Y Katano N Ohmiya Y Niwa K Yamamoto T Kaneko M Nieda K Yokokawa H Goto 2009 A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer Pancreas 38 3 e69 e74 10.1097/MPA.0b013e318197a9e3 19276867 10.1097/MPA. 0b013e318197a9e3 1:CAS:528:DC%2BD1MXjsVyqtrg%3D
19. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford J Dancey S Arbuck S Gwyther M Mooney L Rubinstein L Shankar L Dodd R Kaplan D Lacombe J Verweij 2009 New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1) Eur J Cancer 45 2 228 247 10.1016/j.ejca.2008.10.026 19097774 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
20. V Heinemann S Boeck A Hinke R Labianca C Louvet 2008 Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 1 82 10.1186/1471-2407-8-82 18373843 10.1186/1471-2407-8-82 (Pubitemid 351552578)
21. M Carpelan-Holmstrom S Nordling E Pukkala R Sankila J Luttges G Kloppel C Haglund 2005 Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the finnish cancer registry Gut 54 3 385 387 10.1136/gut.2004.047191 15710987 10.1136/gut.2004.047191 1:STN:280: DC%2BD2M%2FotFGqtQ%3D%3D (Pubitemid 40299095)
22. KD Holen DS Klimstra A Hummer M Gonen K Conlon M Brennan LB Saltz 2002 Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors J Clin Oncol 20 24 4673 4678 12488412 10.1200/JCO.2002.02.005 (Pubitemid 36025284)
23. Butturini G, Pisano M, Scarpa A, D'Onofrio M, Auriemma A, Bassi C Aggressive approach to acinar cell carcinoma of the pancreas: A single-institution experience and a literature review. Langenbecks Arch Surg. doi: 10.1007/s00423-010-0706-2
24. B Kubuschok X Xie R Jesnowski KD Preuss BF Romeike F Neumann E Regitz G Pistorius M Schilling P Scheunemann JR Izbicki JM Lohr M Pfreundschuh 2004 Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis Int J Cancer 109 4 568 575 10.1002/ijc.20006 14991579 10.1002/ijc.20006 1:CAS:528:DC%2BD2cXislCisrc%3D (Pubitemid 38339648)
25. C Menard F Martin L Apetoh F Bouyer F Ghiringhelli 2008 Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity Cancer Immunol Immunother 57 11 1579 1587 10.1007/s00262-008-0505-6 18369619 10.1007/s00262-008-0505-6 1:CAS:528:DC%2BD1cXhtVejsbbE
26. JL Gulley RA Madan PM Arlen 2007 Enhancing efficacy of therapeutic vaccinations by combination with other modalities Vaccine 25 Suppl 2 B89 B96 10.1016/j.vaccine.2007.04.091 17573164 10.1016/j.vaccine.2007.04.091 1:CAS:528:DC%2BD2sXhtFequr3J (Pubitemid 47488548)
27. W von Bernstorff M Voss S Freichel A Schmid I Vogel C Johnk D Henne-Bruns B Kremer H Kalthoff 2001 Systemic and local immunosuppression in pancreatic cancer patients Clin Cancer Res 7 3 Suppl 925s 932s (Pubitemid 33600947)
28. N Hiraoka K Onozato T Kosuge S Hirohashi 2006 Prevalence of foxp3 + regulatory t cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions Clin Cancer Res 12 18 5423 5434 10.1158/1078-0432.CCR-06-0369 17000676 10.1158/1078-0432.CCR-06-0369 1:CAS:528:DC%2BD28XpvFShsLc%3D (Pubitemid 44497257)
29. Y Lin S Kikuchi A Tamakoshi Y Obata K Yagyu Y Inaba M Kurosawa T Kawamura Y Motohashi T Ishibashi 2006 Serum transforming growth factor-beta1 levels and pancreatic cancer risk: A nested case-control study (japan) Cancer Causes Control 17 8 1077 1082 10.1007/s10552-006-0048-0 16933058 10.1007/s10552-006- 0048-0 (Pubitemid 44290772)